ImmunoPrecise Antibodies Custom Monoclonal and Polyclonal Antibody Development

ImmunoPrecise Antibodies is a leading provider of custom monoclonal and polyclonal antibody development. With more than 20 years’ experience, our know-how and expertise yield the highest success rates and some of the fastest turnaround times in the industry.

Clients trust us to get the results they need. With our fast, high-quality, professional service, ImmunoPrecise looks forward to working with you on your next antibody project.

Custom monoclonal antibody (mAb) development

Rapid Prime is ImmunoPrecise’s trademark custom monoclonal antibody development service. This rapid immunisation strategy saves weeks on custom hybridoma development. When coupled with our single-step cloning procedure, Clone-EZ, positive hybridoma cell lines are identified in 32 days.

This animal-friendly immunisation strategy does not employ Freund’s adjuvant and reduces the immunisation phase from 84 days to 18 days without limiting affinity maturation of the B-cells, while consistently producing mAbs of all isotypes.

The Rapid Prime method has also been extremely useful for generating monoclonal antibodies against conformational epitopes. This gives ImmunoPrecise a distinct edge over less progressive companies’ protocols and allows clients to conduct research or market valuable mAbs in the fastest time possible.

Custom polyclonal antibody development

ImmunoPrecise is a high-quality production facility capable of developing custom polyclonal antibodies in a variety of species, including rabbit, goat and sheep, against a variety of immunogens. Immunogens include individual amino acids, in/organic compounds, peptides and post-translational modifications such as phosphorylation, acetylation and methylation, along with native and recombinant proteins.

Ascites and bioreactor antibody development

ImmunoPrecise is an accredited manufacturing facility capable of small-scale and bulk production of any custom antibody clone, both in vitro and as ascites.

Cryopreservation services

Our cryopreservation services division offers storage for cell lines, tissues, RNA, DNA, plasmids and antibodies. ImmunoPrecise safeguards valuable biological materials by utilising the latest in liquid nitrogen storage technology. Our storage tanks are regularly monitored and highly secure. Low-level alarms and daily inspections ensure sample safety.

Antibody products and hybridoma out-licensing

ImmunoPrecise offers a growing list of high-quality antibody products to the research community. We have also developed an array of antibodies for out-licensing.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Immunoprecise Antibodies Issues Letter to Shareholders

Life sciences technology and product company Immunoprecise has announced that its president Thomas D'Orazio has released a letter to shareholders to reflect on why he has also accepted the role of chief executive officer (CEO) following the completion of a $4.3 million financing of the TSX Venture exchange, which has now begun trading.

White Papers

The ImmunoPrecise Rapid Prime System Reduces the Immunization Stage of Hybridoma Production to 18 Days

The ImmunoPrecise Rapid Prime System Reduces the Immunization Stage of Hybridoma Production to 18 Days

Address
ImmunoPrecise Antibodies

Unit 3204-4464

Markham Street

Victoria

BCV8Z7X8

Other

Canada

+1 250 483 0308 +1 250 483 0309 www.immunoprecise.com

ImmunoPrecise Antibodies Images

Products and Services

Video

Press Release

24 January 2017

Life sciences technology and product company Immunoprecise has announced that its president Thomas D'Orazio has released a letter to shareholders to reflect on why he has also accepted the role of chief executive officer (CEO) following the completion of a $4.3 million financing of the TSX Venture exchange, which has now begun trading.

Read more
29 May 2007

ACE Pharmaceuticals today announced that the first patient has entered the Phase III trial also known as the Levamisole trial. This trial was accepted by the EMEA by November 2006. The goal of this trial, which was accepted by the EMEA in November 2006, is to assess the efficacy and sa

Read more

Regional Offices

ImmunoPrecise Antibodies

Unit 3204-4464

Markham Street

Victoria

BCV8Z7X8

Other

Canada

+1 250 483 0308 +1 250 483 0309 www.immunoprecise.com

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.